You are here

Share:

Search Technologies

Showing 1-20 of 139 results found

Treatment of Glioma, Glioblastoma, and Astrocytoma

The National Institute on Aging, Laboratory of Clinical Investigation is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of fenoterol and fenoterol analogs in the front line and adjuvant treatment of CNS tumors and other B2 AR expressing tumors.

Synergistic Combination Agent for Cancer Therapy

The Nanotechnology Characterization Laboratory of the Frederick National Laboratory for Biomedical Research seeks parties interested in collaborative research to co-develop a ceramide and vinca alkaloid combination therapy for treatment of cancer.

Ketamine Metabolites for the Treatment of Depression and Pain

The National Institute on Aging, Laboratory of Clinical Investigation, is seeking parties interested in collaborative research to co-develop ketamine metabolites for the treatment of different forms of depression and for alleviating pain.

MUC-1 Tumor Antigen Agonist Epitopes for Enhancing T-cell Responses to Human Tumors

Scientists at NIH have identified 7 new agonist epitopes of the MUC-1 tumor associated antigen. Compared to their native epitope counterparts, peptides reflecting these agonist epitopes have been shown to enhance the generation of human tumor cells, which in turn have a greater ability to kill human tumor cells endogenously expressing the native MUC-1 epitope.

Angiogenesis-Based Cancer Therapeutic

The National Cancer Institute's Urologic Oncology Branch seeks interested parties to co-develop antagonists to VEGF-A and hepatocyte growth factor (HGF) that block signal transduction and associated cellular responses.

Co-Transcriptional Assembly of Modified RNA Nanoparticles

The National Cancer Institute’s Nanobiology Program seeks parties interested in collaborative research to co-develop a method to generate RNA molecules suitable for nanoparticle and biomedical applications.

HIV-1 Entry Inhibitor

The National Cancer Institute’s Nanobiology Program seeks parties to co-develop soluble forms of CD4 as potent HIV-1 therapeutics.

Human Antibodies Against Middle East Respiratory Syndrome Coronavirus

The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to co-develop antibody-based therapeutic against MERS-CoV, including animal studies, cGMP manufacturing, and clinical trials.

Anti-Tumor Agents That Effect Premature Chromosome Condensation

The National Cancer Institute Laboratory of Molecular Pharmacology seeks parties interested in licensing or collaborative research to co-evelop, evaluate, or commercialize lasonolide compounds as novel anti-cancer agents.

Pages